Repligen Corp vs. Tarsus Pharmaceuticals, Inc. Common Stock
Repligen Corp and Tarsus Pharmaceuticals, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| RGEN | TARS | |
|---|---|---|
| Market Cap | $9.30 billion | $3.05 billion |
| Revenue (TTM) | $785.10 million | — |
| Net Income (TTM) | $41.54 million | — |
RGEN leads on 1 of 1 size & scale factors.
Valuation
| RGEN | TARS | |
|---|---|---|
| P/E Ratio | 225.71 | — |
| Price / Book | 4.40 | — |
| Price / Sales | 11.84 | — |
RGEN and TARS split the valuation factors evenly.
Profitability
| RGEN | TARS | |
|---|---|---|
| Net Margin | 5.29% | — |
| Return on Equity | 1.97% | — |
RGEN and TARS split the profitability factors evenly.
Risk & Sentiment
| RGEN | TARS | |
|---|---|---|
| Short Interest | 7.13% | 0.31% |
TARS leads on 1 of 1 risk & sentiment factors.
Dig deeper: RGEN overview, RGEN financials, TARS overview, TARS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.